menu
    • menu
    [{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bioprojet Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioprojet Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bioprojet Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioprojet Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"TPM-1116","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Bioprojet Pharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"Bioprojet Pharma \/ Harmony Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Bioprojet Pharma \/ Harmony Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Bioprojet Pharma

    Menu

    Bioprojet Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioprojet Pharma

                            France arrow
                            ELCC
                            Not Confirmed

                            Bioprojet Pharma

                            France arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TPM-1116

                            Therapeutic Area : Sleep

                            Study Phase : Preclinical

                            Sponsor : Harmony Biosciences

                            Deal Size : $393.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Harmony Enters Agreement to Develop Oral Orexin-2 Agonist TPM-1116

                            Details : Through the Licensing Agreement, Bioprojet will develop, manufacture, and commercialize TPM-1116, a selective oral orexin-2 receptor agonist for narcolepsy and other sleep/wake disorders.

                            Product Name : TPM-1116

                            Product Type : Small molecule

                            Upfront Cash : $25.5 million

                            April 11, 2024

                            Lead Product(s) : TPM-1116

                            Therapeutic Area : Sleep

                            Highest Development Status : Preclinical

                            Sponsor : Harmony Biosciences

                            Deal Size : $393.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bioprojet Pharma

                            France arrow
                            ELCC
                            Not Confirmed

                            Bioprojet Pharma

                            France arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioprojet: WAKIX® (pitolisant) Receives Approval for The Treatment of Narcolepsy in Children Over 6 Years of ...

                            Details : Wakix (pitolisant) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse.

                            Product Name : Wakix

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 15, 2023

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bioprojet Pharma

                            France arrow
                            ELCC
                            Not Confirmed

                            Bioprojet Pharma

                            France arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioprojet: European Marketing Authorisation for OZAWADE™

                            Details : Ozawade (pitolisant hydrochloride) enhances the activity of histaminergic neurons, promotes wakefulness by blocking H3 autoreceptors and increases the levels of histamine transmitters at the synapse, and is used for Prader-Willi Syndrome.

                            Product Name : Ozawade

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2021

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth